Want to see CSBR full AI Analyst Report?
CSBR Stock Chart & Stats
$4.98
$0.13(2.17%)
At close: 4:00 PM EDT
$4.98
$0.13(2.17%)
Day’s Range― - ―
52-Week Range$4.59 - $8.31
Previous Close$6.14
Volume111.00
Average Volume (3M)10.95K
Market Cap
$68.20M
Enterprise Value$81.67
Total Cash (Recent Filing)$4.36M
Total Debt (Recent Filing)$10.97M
Price to Earnings (P/E)―
Beta0.27
Next Earnings
Dec 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding13,918,569
10 Day Avg. Volume15,714
30 Day Avg. Volume10,951
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)20.93
Price to Sales (P/S)1.39
P/FCF Ratio-16.37
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.1
Revenue Forecast (FY)$65.26M
Bulls Say, Bears Say
Bulls Say
Margin And EBITDA ExpansionImproving gross margin and a sustained run of positive adjusted EBITDA indicate better operating leverage in the core services model. If maintained, this combination can support reinvestment, reduce dependence on external funding, and improve earnings quality over the next several quarters.
Proprietary Oncology Data AdvantageScarce, clinically annotated patient-derived data can differentiate Champions as biopharma sponsors increasingly use AI and machine learning in development decisions. This asset may support repeat demand, strengthen data licensing opportunities, and deepen the company’s strategic relevance.
Services Demand And Revenue GrowthYear-over-year growth alongside healthy translational oncology demand suggests the core fee-for-service business is gaining traction. Continued customer activity and stronger conversion of contracted study value could provide a more durable base for revenue growth and operating improvement.
Bears Say
TTM Revenue Contraction And Volatile ProfitabilityThe sharp TTM revenue decline and repeated movement between profit and loss reduce confidence in earnings durability. Such volatility makes planning and resource allocation harder, and leaves future results more dependent on successful execution and sustained customer project demand.
Cash Burn And Balance-Sheet FragilityNegative operating and free cash flow indicate that the business is currently consuming cash rather than funding itself. Combined with elevated leverage and a small equity base, this reduces financial flexibility and could constrain investment during periods of weaker operating performance.
Lumpy Data Licensing RevenueLumpy licensing revenue makes quarterly performance less predictable and can obscure the underlying pace of customer adoption. Uneven contract timing may also create volatility in cash generation, complicating forecasting and increasing reliance on the steadier services business.
Champions Oncology News
CSBR FAQ
What was Champions Oncology Inc’s price range in the past 12 months?
Champions Oncology Inc lowest stock price was $4.59 and its highest was $8.31 in the past 12 months.
What is Champions Oncology Inc’s market cap?
Champions Oncology Inc’s market cap is $68.20M.
When is Champions Oncology Inc’s upcoming earnings report date?
Champions Oncology Inc’s upcoming earnings report date is Dec 15, 2026 which is in 77 days.
How were Champions Oncology Inc’s earnings last quarter?
Champions Oncology Inc released its earnings results on Sep 10, 2026. The company reported $0.05 earnings per share for the quarter.
Is Champions Oncology Inc overvalued?
According to Wall Street analysts Champions Oncology Inc’s price is currently Overvalued.
Does Champions Oncology Inc pay dividends?
Champions Oncology Inc does not currently pay dividends.
What is Champions Oncology Inc’s EPS estimate?
Champions Oncology Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Champions Oncology Inc have?
Champions Oncology Inc has 13,918,569 shares outstanding.
What happened to Champions Oncology Inc’s price movement after its last earnings report?
Champions Oncology Inc reported an EPS of $0.05 in its last earnings report. Following the earnings report the stock price went up 0.098%.
Which hedge fund is a major shareholder of Champions Oncology Inc?
Currently, no hedge funds are holding shares in CSBR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Champions Oncology Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.31%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
8.98%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Champions Oncology Inc
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
CSBR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly positive overall. Management reported approximately 9% revenue growth, significant gross and oncology services margin expansion, the fifth consecutive quarter of positive adjusted EBITDA, stronger data licensing revenue, healthy services demand, and continued Corellia progress. The main cautions were the remaining GAAP net loss, cash usage, lumpy timing of data licensing revenue, higher sales and marketing expense from planned investment, and uncertainty around the timing of a Corellia funding or licensing outcome.View all CSBR earnings summariesTechnical Analysis
Oncolytics Biotech
―
―
Cardiff Oncology
―
MaxCyte
―
Black Diamond Therapeutics
―
Lantern Pharma
―
Ownership Overview
14.79% Insiders
3.01% Mutual Funds
32.88% Other Institutional Investors
47.02% Public Companies and
Individual Investors